The BioPharmaDispatch analysis of the recently released annual PBS Expenditure and Prescriptions report has confirmed the challenge of assessing the scheme based on spending growth but confirms how it has effectively transformed into two programs. …
Latest Video
New Stories
-
Immutep posts encouraging Phase 2 results as 'Efti' spurs robust anti-tumour activity
November 13, 2025 - - Australian Biotech -
PYC Therapeutics appoints Peter Coleman as new Chair as part of board renewal
November 13, 2025 - - Australian Biotech -
New gene discoveries improve diagnosis of inherited heart disease
November 13, 2025 - - Australian Biotech -
Chimeric Therapeutics reports strong early results from CHM CDH17 Phase 1/2 trial
November 13, 2025 - - Australian Biotech -
Australia joins global WHO task force to tackle antimicrobial resistance
November 13, 2025 - - Latest News -
New post-market review workplan focuses on real-world data and patient outcomes
November 13, 2025 - - Latest News -
Government adds new first-line treatment to the PBS for deadly blood cancer
November 13, 2025 -